Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

被引:283
作者
Goldstein, JA
Ishizaki, T
Chiba, K
deMorais, SMF
Bell, D
Krahn, PM
Evans, DAP
机构
[1] INT MED CTR JAPAN,RES INST,DEPT CLIN PHARMACOL,SHINJUKU KU,TOYAMA 162,JAPAN
[2] KING FAISAL SPECIALIST HOSP & RES CTR,RIYADH 11211,SAUDI ARABIA
[3] RIYADH ARMED FORCES HOSP,RIYADH 11159,SAUDI ARABIA
来源
PHARMACOGENETICS | 1997年 / 7卷 / 01期
关键词
CYP2C19; mephenytoin polymorphism;
D O I
10.1097/00008571-199702000-00008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The 4'-hydroxylation of S-mephenytoin is polymorphic in man. The poor metabolizer (PM) phenotype exhibits a lower frequency in Caucasians (2-5%) compared to Oriental populations (13-23%). Previous studies from our laboratory have described two mutations (CYP2C19(m1) and CYP2C19(m2)) which account for similar to 100% of Oriental and similar to 85% of Caucasian PM alleles. The present study examined whether the genotype predicted the phenotype in Japanese, Filipino and Saudi Arabian populations, and compared the frequencies of the defective CYP2C19 alleles in these populations with those found in European-Americans, Chinese-Taiwanese, and African-Americans from North Carolina. Among 53 Japanese, 15% were PMs and among 52 Filipinos 23% were PMs. Among 97 Saudi Arabians, only two were PMs. There was a complete concordance between genotype and phenotype in all three populations. The incidence of CYP2C19(m1) was 0.23 (95% confidence limits 0.15-0.31) in Japanese, 0.39 (95% confidence limits 0.29-0.48) in Filipinos, 0.32 (95% confidence limits 0.26-0.38) in Chinese-Taiwanese, 0.15 (95% confidence limits 0.10-0.20) in Saudi Arabians, 0.13 (95% confidence limits 0.08-0.17) in European-Americans, and 0.25 in African-Americans from North Carolina (95% confidence limits 0.14-0.31). The incidence of CYP2C19(m1) in Saudi Arabians was similar to that found in European-Americans, and significantly lower-than that found in Oriental populations for African-Americans (p < 0.05). CYP2C19(m2) was not found in European-Americans, Saudi Arabians or African-Americans (95%, confidence limits 0-0.014). The incidence of CYP2C19(m2) in the three Oriental populations ranged from 0.10 (95% confidence limits 0.05-0.17) in Japanese and 0.08 (95% confidence limits 0.03-0.13) in Filipinos to 0.06 (95% confidence limits 0.03-0.08) in Chinese-Taiwanese.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 33 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].
BALIAN, JD ;
SUKHOVA, N ;
HARRIS, JW ;
HEWETT, J ;
PICKLE, L ;
GOLDSTEIN, JA ;
WOOSLEY, RL ;
FLOCKHART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669
[3]   AMITRIPTYLINE PHARMACOKINETICS AND CLINICAL-RESPONSE .2. METABOLIC POLYMORPHISM ASSESSED BY HYDROXYLATION OF DEBRISOQUINE AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M ;
KOEB, L ;
KUPFER, A ;
TINGUELY, D ;
SCHOPF, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (02) :102-112
[4]   GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209
[5]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[6]   A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE [J].
BROSEN, K ;
DEMORAIS, SMF ;
MEYER, UA ;
GOLDSTEIN, JA .
PHARMACOGENETICS, 1995, 5 (05) :312-317
[7]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[8]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[9]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[10]   GENETIC-ANALYSIS OF THE S-MEPHENYTOIN POLYMORPHISM IN A CHINESE POPULATION [J].
DEMORAIS, SMF ;
GOLDSTEIN, JA ;
XIE, HG ;
HUANG, SL ;
LU, YQ ;
XIA, H ;
XIAO, ZS ;
ILE, N ;
ZHOU, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :404-411